The team behind an innovative pilot project has been announced as one of the AF Association “Healthcare Pioneers 2018 – Showcasing Best Practice in AF” winners at the Arrhythmia Alliance Awards Ceremony held at the International Heart Rhythm Congress for implementing genotype-guided dosing of Warfarin for atrial fibrillation to improve anticoagulation control.
Trudie Lobban MBE, Founder and CEO, AF Association on congratulating the 2018 Award winners stated, “The AF Association Healthcare Pioneers Award, is presented to examples of truly innovative best practice covering identification, diagnosis, management, treatment and care of patients with atrial fibrillation (AF), which we summarise as detect, protect, correct and perfect. Each year we share the published Healthcare Pioneers report with commissioners across the NHS urging them to use these case studies as a benchmark to drive improvement in processes and patient pathways for the diagnosis, treatment, and care of AF patients.”
“This year we had an exceptional number of entries, the highest number we have ever received and all were of an excellent standard, demonstrating tremendous innovation to improve the lives of AF patients. We thank everyone who entered, and especially commend those chosen as this year’s Healthcare Pioneers Award winners,” she added.
Professor Sir Munir Pirmohamed from the Wolfson Centre for Personalised Medicine at the University of Liverpool said: “This is a great a collaborative project between the University of Liverpool, the North-West Coast NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC), the Innovation Agency (NW Coast AHSN) and Laboratory of the Government Chemist (LGC) to implement an innovative method for improving dosing of warfarin in the treatment of atrial fibrillation in 3 North West anticoagulation clinics.
“Warfarin remains an important anticoagulant, but there is wide variation in the dose required to anticoagulant patients safely. We have previously shown that variation in warfarin dose requirement is due to a combination of genetic and clinical factors. We developed novel algorithms which incorporated genetic factors – we were able to show in a randomised controlled trial that genetic dosing was more accurate than current dosing used in the NHS. We have then moved this forward to an implementation phase where nurses running the anticoagulant clinics were able to test patient genes (within 45 minutes), and dose them accurately using this information."
The team behind the project included -
Gail Fitzgerald, & Clare Prince, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Wolfson Centre for Personalised Medicine at University of Liverpool, UK
Jennifer Downing, Collaboration For Leadership In Applied Health Research And Care North West Coast (CLAHRC), University of Liverpool, UK
Janet Dearden, Warrington And Halton NHS Foundation Trusts, UK
Lucy Langan, Countess of Chester Hospital NHS Foundation Trust, UK
Janet Davies, Royal Liverpool and Broadgreen University Hospital NHS Trust, UK
Julia Reynolds, Innovation Agency North West Coast, UK
Andrea Jorgensen, University of Liverpool, UK
Munir Pirmohamed, University of Liverpool, and Royal Liverpool and Broadgreen University Hospitals NHS Trust, UK
Read about this project and the other worthy winners at the AF Association Healthcare Pioneers Awards 2018 - click here to see the full report.